Septerna’s Inventory Surges 63% on $2.2 Billion Oral Weight problems Drug Partnership with Novo Nordisk
SOUTH SAN FRANCISCO, Calif., Could 14, 2025 – Septerna, Inc. ($SEPN), a clinical-stage biotechnology firm, noticed its inventory value soar 63.3% to $10.99 in premarket buying and selling after asserting a serious partnership with Novo Nordisk, the maker of the blockbuster weight-loss drug Wegovy. The deal, valued at as much as $2.2 billion, focuses on growing as much as 4 oral small-molecule medication concentrating on G protein-coupled receptors (GPCRs) for weight problems and sort 2 diabetes. Septerna will obtain $200 million in upfront and near-term milestone funds, with potential for added milestones and royalties on business gross sales.
The collaboration leverages Septerna’s Native GPCR Complicated Platform to create oral therapies that might compete with injectable GLP-1 medication like Wegovy and Eli Lilly’s Zepbound. Novo Nordisk, aiming to take care of its lead within the $150 billion weight problems market, good points entry to Septerna’s modern strategy, which targets novel GPCR pathways to boost weight reduction efficacy and tolerability. The partnership follows Novo’s latest challenges, together with disappointing trial information for its next-generation drug CagriSema and a 12% year-to-date inventory decline, whereas Lilly’s shares have risen 13%.
Septerna’s inventory surge displays investor confidence within the deal’s potential, as oral weight problems medication promise better affected person comfort over injections. Posts on X, resembling these from @ZorTrades and @OpenOutcrier, spotlight the market’s enthusiasm, noting Septerna’s $200 million upfront cost and the deal’s $2.2 billion ceiling. Novo Nordisk’s inventory ($NVO) additionally rose 2.4% premarket, signaling optimism about its strategic transfer to bolster its weight problems pipeline.
This partnership aligns with Novo’s earlier 2024 collaborations with U.S. biotech companies Omega Therapeutics and Cellarity Inc., which boosted Omega’s shares practically 100%. Septerna, nonetheless, should navigate a aggressive panorama, with Lilly’s oral GLP-1 drug orforglipron and different contenders like Viking Therapeutics and Construction Therapeutics advancing quickly.
Sources: Reuters, Yahoo Finance, posts on X
